Percutaneous transluminal venous angioplasty is ineffective in correcting chronic cerebrospinal venous insufficiency in patients with multiple sclerosis, according to the first randomized trial of the procedure, presented at the American Academy of Neurology‘s annual meeting.
Researchers studied venous angioplasty in 10 patients with MS in an open-label safety assessment, after which they randomized 19 patients to either angioplasty or a sham control. Primary outcomes included safety at 1 day and 1 month, venous outflow restoration, and new lesion activity and relapse over 6 months.
The researchers concluded that the procedure is not only ineffective but also may exacerbate MS disease activity in the short-term.
ARYAN'S BLOG 